Cargando…

Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus

SIMPLE SUMMARY: New types of bed nets are being developed which contain a pyrethroid plus a second chemical because of the development and increased frequency of mosquito mechanisms to avoid being killed by pyrethroids. When insecticide-treated bed nets are being trialed for efficacy or released ont...

Descripción completa

Detalles Bibliográficos
Autores principales: Lees, Rosemary S., Armistead, Jennifer S., Azizi, Salum, Constant, Edi, Fornadel, Christen, Gimnig, John E., Hemingway, Janet, Impoinvil, Daniel, Irish, Seth R., Kisinza, William, Lissenden, Natalie, Mawejje, Henry D., Messenger, Louisa A., Moore, Sarah, Ngufor, Corine, Oxborough, Richard, Protopopoff, Natacha, Ranson, Hilary, Small, Graham, Wagman, Joseph, Weetman, David, Zohdy, Sarah, Spiers, Angus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144861/
https://www.ncbi.nlm.nih.gov/pubmed/35621770
http://dx.doi.org/10.3390/insects13050434
_version_ 1784716151723393024
author Lees, Rosemary S.
Armistead, Jennifer S.
Azizi, Salum
Constant, Edi
Fornadel, Christen
Gimnig, John E.
Hemingway, Janet
Impoinvil, Daniel
Irish, Seth R.
Kisinza, William
Lissenden, Natalie
Mawejje, Henry D.
Messenger, Louisa A.
Moore, Sarah
Ngufor, Corine
Oxborough, Richard
Protopopoff, Natacha
Ranson, Hilary
Small, Graham
Wagman, Joseph
Weetman, David
Zohdy, Sarah
Spiers, Angus
author_facet Lees, Rosemary S.
Armistead, Jennifer S.
Azizi, Salum
Constant, Edi
Fornadel, Christen
Gimnig, John E.
Hemingway, Janet
Impoinvil, Daniel
Irish, Seth R.
Kisinza, William
Lissenden, Natalie
Mawejje, Henry D.
Messenger, Louisa A.
Moore, Sarah
Ngufor, Corine
Oxborough, Richard
Protopopoff, Natacha
Ranson, Hilary
Small, Graham
Wagman, Joseph
Weetman, David
Zohdy, Sarah
Spiers, Angus
author_sort Lees, Rosemary S.
collection PubMed
description SIMPLE SUMMARY: New types of bed nets are being developed which contain a pyrethroid plus a second chemical because of the development and increased frequency of mosquito mechanisms to avoid being killed by pyrethroids. When insecticide-treated bed nets are being trialed for efficacy or released onto the market it is essential to measure how effective the net is in killing mosquitoes, which includes testing how quickly insecticide is lost or degraded due to routine wear and tear. Pyrethroid-resistant mosquitoes are needed to test the effectiveness and insecticidal persistence of the second chemical, because they are not all killed by the pyrethroid, allowing the killing effect of the two chemicals to be evaluated independently. However, because resistance status varies between populations of mosquitoes that possess different resistance mechanisms, and because resistance intensity in a population can change over time, a method is needed to characterise the resistant mosquitoes. A focus group of experts discussed how this should best be done, considering pros and cons of different approaches, and co-wrote a protocol, which will be valuable for malaria control programmes and stakeholders wanting to test the effective lifespan of a new bed net in terms of the active ingredient bioefficacy. ABSTRACT: Durability monitoring of insecticide-treated nets (ITNs) containing a pyrethroid in combination with a second active ingredient (AI) must be adapted so that the insecticidal bioefficacy of each AI can be monitored independently. An effective way to do this is to measure rapid knock down of a pyrethroid-susceptible strain of mosquitoes to assess the bioefficacy of the pyrethroid component and to use a pyrethroid-resistant strain to measure the bioefficacy of the second ingredient. To allow robust comparison of results across tests within and between test facilities, and over time, protocols for bioefficacy testing must include either characterisation of the resistant strain, standardisation of the mosquitoes used for bioassays, or a combination of the two. Through a series of virtual meetings, key stakeholders and practitioners explored different approaches to achieving these goals. Via an iterative process we decided on the preferred approach and produced a protocol consisting of characterising mosquitoes used for bioefficacy testing before and after a round of bioassays, for example at each time point in a durability monitoring study. We present the final protocol and justify our approach to establishing a standard methodology for durability monitoring of ITNs containing pyrethroid and a second AI.
format Online
Article
Text
id pubmed-9144861
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91448612022-05-29 Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus Lees, Rosemary S. Armistead, Jennifer S. Azizi, Salum Constant, Edi Fornadel, Christen Gimnig, John E. Hemingway, Janet Impoinvil, Daniel Irish, Seth R. Kisinza, William Lissenden, Natalie Mawejje, Henry D. Messenger, Louisa A. Moore, Sarah Ngufor, Corine Oxborough, Richard Protopopoff, Natacha Ranson, Hilary Small, Graham Wagman, Joseph Weetman, David Zohdy, Sarah Spiers, Angus Insects Guidelines SIMPLE SUMMARY: New types of bed nets are being developed which contain a pyrethroid plus a second chemical because of the development and increased frequency of mosquito mechanisms to avoid being killed by pyrethroids. When insecticide-treated bed nets are being trialed for efficacy or released onto the market it is essential to measure how effective the net is in killing mosquitoes, which includes testing how quickly insecticide is lost or degraded due to routine wear and tear. Pyrethroid-resistant mosquitoes are needed to test the effectiveness and insecticidal persistence of the second chemical, because they are not all killed by the pyrethroid, allowing the killing effect of the two chemicals to be evaluated independently. However, because resistance status varies between populations of mosquitoes that possess different resistance mechanisms, and because resistance intensity in a population can change over time, a method is needed to characterise the resistant mosquitoes. A focus group of experts discussed how this should best be done, considering pros and cons of different approaches, and co-wrote a protocol, which will be valuable for malaria control programmes and stakeholders wanting to test the effective lifespan of a new bed net in terms of the active ingredient bioefficacy. ABSTRACT: Durability monitoring of insecticide-treated nets (ITNs) containing a pyrethroid in combination with a second active ingredient (AI) must be adapted so that the insecticidal bioefficacy of each AI can be monitored independently. An effective way to do this is to measure rapid knock down of a pyrethroid-susceptible strain of mosquitoes to assess the bioefficacy of the pyrethroid component and to use a pyrethroid-resistant strain to measure the bioefficacy of the second ingredient. To allow robust comparison of results across tests within and between test facilities, and over time, protocols for bioefficacy testing must include either characterisation of the resistant strain, standardisation of the mosquitoes used for bioassays, or a combination of the two. Through a series of virtual meetings, key stakeholders and practitioners explored different approaches to achieving these goals. Via an iterative process we decided on the preferred approach and produced a protocol consisting of characterising mosquitoes used for bioefficacy testing before and after a round of bioassays, for example at each time point in a durability monitoring study. We present the final protocol and justify our approach to establishing a standard methodology for durability monitoring of ITNs containing pyrethroid and a second AI. MDPI 2022-05-06 /pmc/articles/PMC9144861/ /pubmed/35621770 http://dx.doi.org/10.3390/insects13050434 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Guidelines
Lees, Rosemary S.
Armistead, Jennifer S.
Azizi, Salum
Constant, Edi
Fornadel, Christen
Gimnig, John E.
Hemingway, Janet
Impoinvil, Daniel
Irish, Seth R.
Kisinza, William
Lissenden, Natalie
Mawejje, Henry D.
Messenger, Louisa A.
Moore, Sarah
Ngufor, Corine
Oxborough, Richard
Protopopoff, Natacha
Ranson, Hilary
Small, Graham
Wagman, Joseph
Weetman, David
Zohdy, Sarah
Spiers, Angus
Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus
title Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus
title_full Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus
title_fullStr Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus
title_full_unstemmed Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus
title_short Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus
title_sort strain characterisation for measuring bioefficacy of itns treated with two active ingredients (dual-ai itns): developing a robust protocol by building consensus
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144861/
https://www.ncbi.nlm.nih.gov/pubmed/35621770
http://dx.doi.org/10.3390/insects13050434
work_keys_str_mv AT leesrosemarys straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT armisteadjennifers straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT azizisalum straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT constantedi straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT fornadelchristen straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT gimnigjohne straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT hemingwayjanet straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT impoinvildaniel straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT irishsethr straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT kisinzawilliam straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT lissendennatalie straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT mawejjehenryd straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT messengerlouisaa straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT mooresarah straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT nguforcorine straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT oxboroughrichard straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT protopopoffnatacha straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT ransonhilary straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT smallgraham straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT wagmanjoseph straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT weetmandavid straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT zohdysarah straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus
AT spiersangus straincharacterisationformeasuringbioefficacyofitnstreatedwithtwoactiveingredientsdualaiitnsdevelopingarobustprotocolbybuildingconsensus